Modality
Fusion Protein
MOA
CAR-T BCMA
Target
PLK4
Pathway
Notch
Breast CaEndometrial Ca
Development Pipeline
Preclinical
Nov 2021
→ Oct 2031
PreclinicalCurrent
NCT05884431
2,089 pts·Endometrial Ca
2021-11→2031-10·Completed
2,089 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-07-069mo agoBTD· Endometrial Ca
2031-10-115.5y awayInterim· Endometrial Ca
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Complet…
Catalysts
BTD
2025-07-06 · 9mo ago
Endometrial Ca
Interim
2031-10-11 · 5.5y away
Endometrial Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05884431 | Preclinical | Endometrial Ca | Completed | 2089 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |